Report overview
Dendritic cells (DCs) are one of the major antigen-presenting cells found in lymphoid organs. Main function of the dendritic cells is antigen display and activation of T-cells. Antigen display presents the identity of pathogen to T-cells for their identification and elimination from the body. These cells have proficiency of capturing and processing tumor antigens, which activates expression of lymphocyte co-stimulatory molecules. Consequently, it results in secretion of cytokines to initiate immune response. Over 60 dendritic cell and tumor cell cancer vaccines are currently in clinical / preclinical stages of development; 70% of the pipeline comprises of dendritic cell cancer vaccines.
This report aims to provide a comprehensive presentation of the global market for Dendritic Cell Cancer Vaccine Immunotherapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Dendritic Cell Cancer Vaccine Immunotherapy. This report contains market size and forecasts of Dendritic Cell Cancer Vaccine Immunotherapy in global, including the following market information:
Global Dendritic Cell Cancer Vaccine Immunotherapy Market Revenue, 2018-2023, 2024-2030, ($ millions)
Global top five companies in 2022 (%)
The global Dendritic Cell Cancer Vaccine Immunotherapy market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Provenge Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Dendritic Cell Cancer Vaccine Immunotherapy include Lineage Cell Therapeutics, AVAX Technologies, DCPrime, Gradalis, Heat Biologics, ImmunoCellular Therapeutics, Immunicum, MolecuVax and Northwest Biotherapeutics, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Dendritic Cell Cancer Vaccine Immunotherapy companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Dendritic Cell Cancer Vaccine Immunotherapy Market, by Type, 2018-2023, 2024-2030 ($ millions)
Global Dendritic Cell Cancer Vaccine Immunotherapy Market Segment Percentages, by Type, 2022 (%)
Provenge
Apceden
CreaVax
Others
Global Dendritic Cell Cancer Vaccine Immunotherapy Market, by Application, 2018-2023, 2024-2030 ($ millions)
Global Dendritic Cell Cancer Vaccine Immunotherapy Market Segment Percentages, by Application, 2022 (%)
Pediatrics
Adults
Global Dendritic Cell Cancer Vaccine Immunotherapy Market, By Region and Country, 2018-2023, 2024-2030 ($ Millions)
Global Dendritic Cell Cancer Vaccine Immunotherapy Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Dendritic Cell Cancer Vaccine Immunotherapy revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Dendritic Cell Cancer Vaccine Immunotherapy revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Lineage Cell Therapeutics
AVAX Technologies
DCPrime
Gradalis
Heat Biologics
ImmunoCellular Therapeutics
Immunicum
MolecuVax
Northwest Biotherapeutics
Pique Therapeutics
Regeneus
Tessa Therapeutics
Vaccinogen
XEME Biopharma
Outline of Major Chapters:
Chapter 1: Introduces the definition of Dendritic Cell Cancer Vaccine Immunotherapy, market overview.
Chapter 2: Global Dendritic Cell Cancer Vaccine Immunotherapy market size in revenue.
Chapter 3: Detailed analysis of Dendritic Cell Cancer Vaccine Immunotherapy company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Dendritic Cell Cancer Vaccine Immunotherapy in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
